These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 14627)

  • 1. Labetalol (AH5158), a competitive alpha- and beta-receptor blocking drug, in the management of hypertension.
    Rosei EA; Brown JJ; Fraser R; Lever AF; Morton JJ; Robertson JI; Trust PM
    Aust N Z J Med; 1976 Aug; 6(3 Suppl):83-8. PubMed ID: 14627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intravenous labetalol on blood pressure, angiotensin II and aldosterone in hypertension: comparison with propranolol.
    Rosei EA; Trust PM; Brown JJ; Fraser R; Lever AF; Morton JJ; Robertson JI
    Clin Sci Mol Med Suppl; 1976 Dec; 3():497s-499s. PubMed ID: 1071671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
    Prichard BN
    Drugs; 1984; 28 Suppl 2():51-68. PubMed ID: 6151891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Labetalol, an alpha- and beta-adrenergic blocking drug in the treatment of hypertension.
    Rosei EA; Fraser R; Morton JJ; Brown JJ; Lever AF; Robertson JI; Trust PM
    Am Heart J; 1977 Jan; 93(1):124-5. PubMed ID: 12654
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of blood pressure angiotensin II and aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with propranolol.
    Trust PM; Rosei EA; Brown JJ; Fraser R; Lever AF; Morton JJ; Robertson JI
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):799-803. PubMed ID: 791333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol.
    Rosei EA; Brown JJ; Lever AF; Robertson AS; Robertson JI; Trust PM
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):809-15. PubMed ID: 990158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Labetalol: a review of its pharmacology and therapeutic use in hypertension.
    Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1978 Apr; 15(4):251-70. PubMed ID: 25757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive effect of labetalol, a new alpha- and beta-adrenergic blocking agent.
    Hansson L; Hänel B
    Int J Clin Pharmacol Biopharm; 1976 Oct; 14(3):195-8. PubMed ID: 12115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combined alpha- and beta-adrenergic blocker labetalol and propranolol in the treatment of high blood pressure: similarities and differences.
    Weber MA; Drayer JI; Kaufman CA
    J Clin Pharmacol; 1984; 24(2-3):103-12. PubMed ID: 6143765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Labetalol, a new alpha- and beta-adrenoreceptor blocking agent, in hypertension.
    Hansson L; Hänel B
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):763-4. PubMed ID: 10952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous labetalol in the treatment of severe hypertension.
    Cumming AM; Brown JJ; Lever AF; Robertson JI
    Br J Clin Pharmacol; 1982 Jun; 13(1 Suppl):93S-96S. PubMed ID: 7093105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of labetalol in hypertensive patients during discontinuation of clonidine therapy.
    Rosenthal T; Rabinowitz B; Boichis H; Elazar E; Brauner A; Neufeld HN
    Eur J Clin Pharmacol; 1981; 20(4):237-40. PubMed ID: 6273179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of labetalol, the first alpha- and beta-blocking agent.
    Kanto JH
    Int J Clin Pharmacol Ther Toxicol; 1985 Nov; 23(11):617-28. PubMed ID: 2867049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects.
    Mehta J; Cohn JN
    Circulation; 1977 Feb; 55(2):370-5. PubMed ID: 12880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood pressure reduction by incremental infusion of labetalol in patients with severe hypertension.
    Cummings AM; Brown JJ; Fraser R; Lever AF; Morton JJ; Richards DA; Robertson JI
    Br J Clin Pharmacol; 1979 Oct; 8(4):359-64. PubMed ID: 508511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of combined alpha-beta-blockade. I.
    Louis WJ; McNeil JJ; Drummer OH
    Drugs; 1984; 28 Suppl 2():16-34. PubMed ID: 6151889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rebound hypertension following abrupt cessation of clonidine and metoprolol. Treatment with labetalol.
    Mehta JL; Lopez LM
    Arch Intern Med; 1987 Feb; 147(2):389-90. PubMed ID: 3813760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Labetalol in the treatment of severe essential hypertension: relationship between arterial blood pressure, plasma catecholamines, plasma renin activity, plasma aldosterone and body weight.
    Kornerup HJ; Pedersen EB; Christensen NJ; Pedersen A; Pedersen G
    Acta Med Scand Suppl; 1979; 625():59-64. PubMed ID: 34981
    [No Abstract]   [Full Text] [Related]  

  • 19. Intravenous labetalol in the management of severe hypertension and hypertensive emergencies.
    Cressman MD; Vidt DG; Gifford RW; Moore WS; Wilson DJ
    Am Heart J; 1984 May; 107(5 Pt 1):980-5. PubMed ID: 6720529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Labetalol: an alpha- and beta-adrenoceptor blocking drug.
    Michelson EL; Frishman WH
    Ann Intern Med; 1983 Oct; 99(4):553-5. PubMed ID: 6137987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.